Dr. Robert Bruce Montgomery, MD

Dr. Montgomery practices at UW Medical Center - Montlake in Seattle, Washington, part of University of Washington.

Dr. Montgomery's NPI, 1124138219, was assigned on August 30, 2006. Dr. Montgomery graduated from Duke University School of Medicine in 1987. Dr. Montgomery holds Washington license MD00027441.

Dr. Montgomery's primary practice is UW Medical Center - Montlake, at 1959 NE Pacific St Box 356151, Seattle, WA 98195 in King County. The practice phone is (206) 598-3300.

Dr. Montgomery's primary practice is UW Medical Center - Montlake in Seattle, Washington, part of University of Washington. Dr. Montgomery is also affiliated with Fred Hutchinson Cancer Center. The medical group on file is UW Physicians. Dmand AI also links Dr. Montgomery to 3 more hospitals and 1 hospital outpatient department, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Montgomery practices, 6 sites in all. Vendor and product names are available with a free account.

Medical oncology is Dr. Montgomery's primary specialty in the NPI Registry, under taxonomy code 207RX0202X. Dr. Montgomery is board certified in medical oncology by the American Board of Internal Medicine. Dr. Montgomery is licensed in Washington.

CMS data shows 362 Medicare services from Dr. Montgomery across 4 procedure codes in 2024, for 140 Medicare patients. Medicare paid $23,435 for them. Every service was in a facility, such as a hospital, rather than an office.

CMS counts 140 Medicare patients who saw Dr. Montgomery in 2024. The largest group is 75 to 84, with 65 patients. 75% of them have cancer, and 69% have high cholesterol. Their average risk score is 1.70, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Montgomery's median patient age at 75, with 3% women.

In 2024, Dr. Montgomery wrote 236 Medicare Part D claims for 54 patients. 82% of them were for generic drugs. CMS names the drug for 178 of them, across 8 drugs with 11 or more claims each, at $437,524 in total drug cost. In 2023, CMS named 138 claims across 8 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 94 out of 100 for Dr. Montgomery for performance year 2024, reported through an alternative payment model (APM). Dr. Montgomery accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Montgomery as offering telehealth.

Dmand AI links 41 papers to Dr. Montgomery, published from 2010 to 2025. 2024 was the busiest year, with 7. The most frequent topics are Prostatic Neoplasms, Prostatic Neoplasms, Castration-Resistant and Neoplasm Metastasis. Dr. Montgomery has published most often in Clin Genitourin Cancer. Dr. Montgomery's most frequent co-authors are Petros Grivas, MD, Andrew Caleb Hsieh, MD and Elahe A. Mostaghel, MD, PhD.

Dmand AI links Dr. Montgomery to 6 clinical trials, 2 of them phase 1/2 studies. 1 is still active or recruiting. Conditions studied include Prostatic Neoplasms, Prostatic Diseases and Urinary Bladder Neoplasms. University of Washington sponsors the most, 5.

CMS Open Payments shows 23 general payments to Dr. Montgomery from 5 drug and device companies from 2016 to 2025. Consulting fees make up the largest share, 78% of the total. Janssen Pharmaceuticals, Inc paid the most, $8,460. It also lists 1 research payment totaling $965 in 2016.

Dr. Montgomery graduated from Duke University School of Medicine in 1987.